Skip to main content
. Author manuscript; available in PMC: 2008 Mar 26.
Published in final edited form as: N Engl J Med. 2003 Jul 31;349(5):427–434. doi: 10.1056/NEJMoa021491

Figure 1. Kaplan–Meier Analysis of Survival Free of Tumor Progression for Patients Receiving High-Dose Bevacizumab (Panel A) or Low-Dose Bevacizumab (Panel B), as Compared with Placebo.

Figure 1

The high dose of bevacizumab was 10 mg per kilogram of body weight. The low dose of bevacizumab was 3 mg per kilogram. Doses were given every two weeks. P values were calculated by the log-rank test.